Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arovella Therapeutics Limited ( (AU:ALA) ) just unveiled an announcement.
Arovella Therapeutics has announced the retirement of Interim Chair and Non-Executive Director Dr Elizabeth Stoner and Non-Executive Director Gary Phillips, both effective 9 February 2026. In response to these significant board changes, the company will undertake a skills review and subsequently appoint a new Chair.
Chief executive Dr Michael Baker credited Stoner and Phillips with guiding Arovella through its pivot to a cell therapy focus and helping advance its CAR-iNKT platform from preclinical to IND-ready status. With the recent acceptance of the IND for lead candidate ALA-101 and ongoing work on solid tumour program ALA-105, the company emphasised that the board transition comes as it prepares to dose its first patient and strengthen governance capabilities for its next phase of growth.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is an Australian biotechnology company focused on developing an invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers and solid tumours. Its lead product, ALA-101, is an allogeneic CAR19-iNKT cell therapy targeting CD19, and it is also advancing CLDN18.2-targeting technology for solid tumour indications.
Average Trading Volume: 1,038,715
Technical Sentiment Signal: Hold
Current Market Cap: A$108.1M
Learn more about ALA stock on TipRanks’ Stock Analysis page.